Top

Open Access 13-04-2024 | Deep Brain Stimulation | Neurology and Preclinical Neurological Studies - Review Article

Advanced therapies in Parkinson’s disease: an individualized approach to their indication

Authors: Nils Schröter, Bastian E. A. Sajonz, Wolfgang H. Jost, Michel Rijntjes, Volker A. Coenen, Sergiu Groppa

Published in: Journal of Neural Transmission

Abstract

Device aided therapies (DAT) comprising the intrajejunal administration of levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel (LECIG), the continuous subcutaneous application of foslevodopa/foscarbidopa or apomorphine infusion (CSAI) and deep brain stimulation (DBS) are used to treat Parkinson’s disease with insufficient symptom alleviation under intensified pharmacotherapy. These DAT significantly differ in their efficacy profiles, indication, invasiveness, contraindications, and potential side effects. Usually, the evaluation of all these procedures is conducted simultaneously at the same point in time. However, as disease progression and symptom burden is extremely heterogeneous, clinical experience shows that patients reach the individual milestones for a certain therapy at different points in their disease course. Therefore, advocating for an individualized therapy evaluation for each DAT, requiring an ongoing evaluation. This necessitates that, during each consultation, the current symptomatology should be analyzed, and the potential suitability for a DAT be assessed. This work represents a critical interdisciplinary appraisal of these therapies in terms of their individual profiles and compares these DAT regarding contraindications, periprocedural considerations as well as their efficacy regarding motor- and non-motor deficits, supporting a personalized approach.

Aldred J, Freire-Alvarez E, Amelin AV et al (2023) Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy results from a 12-Month, Single-Arm, Open-Label, phase 3 study. Neurol Ther 12:1937–1958. https://doi.org/10.1007/s40120-023-00533-1CrossRefPubMedPubMedCentral

Antonini A, Poewe W, Chaudhuri KR et al (2017) Levodopa-carbidopa intestinal gel in advanced Parkinson’s: final results of the GLORIA registry. Parkinsonism Relat Disord 45:13–20. https://doi.org/10.1016/j.parkreldis.2017.09.018CrossRefPubMed

Antonini A, Moro E, Godeiro C, Reichmann H (2018) Medical and surgical management of advanced Parkinson’s disease. Mov Disord 33:900–908. https://doi.org/10.1002/mds.27340CrossRefPubMed

Antonini A, Odin P, Schmidt P et al (2021) Validation and clinical value of the MANAGE-PD tool: a clinician-reported tool to identify Parkinson’s disease patients inadequately controlled on oral medications. Parkinsonism Relat Disord 92:59–66. https://doi.org/10.1016/j.parkreldis.2021.10.009CrossRefPubMed

Antonini A, D’Onofrio V, Guerra A (2023) Current and novel infusion therapies for patients with Parkinson’s disease. J Neural Transm. https://doi.org/10.1007/s00702-023-02693-8CrossRefPubMed

Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson Disease: a review. JAMA 323:548–560. https://doi.org/10.1001/jama.2019.22360CrossRefPubMed

Artusi CA, Dwivedi AK, Romagnolo A et al (2019) Association of Subthalamic Deep Brain Stimulation with Motor, Functional, and pharmacologic outcomes in patients with monogenic Parkinson Disease: a systematic review and Meta-analysis. JAMA Netw Open 2:e187800. https://doi.org/10.1001/jamanetworkopen.2018.7800CrossRefPubMedPubMedCentral

Avenali M, Zangaglia R, Cuconato G et al (2024) Are patients with GBA–Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort. J Neurol Neurosurg Psychiatry 95:309–315. https://doi.org/10.1136/jnnp-2023-332387CrossRefPubMed

Benabid AL, Pollak P, Gervason C et al (1991) Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 337:403–406. https://doi.org/10.1016/0140-6736(91)91175-tCrossRefPubMed

Bloem BR, Okun MS, Klein C (2021) Parkinson’s disease. Lancet 397:2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-XCrossRefPubMed

Bouthour W, Mégevand P, Donoghue J et al (2019) Biomarkers for closed-loop deep brain stimulation in Parkinson disease and beyond. Nat Rev Neurol 15:343–352. https://doi.org/10.1038/s41582-019-0166-4CrossRefPubMed

Bove F, Mulas D, Cavallieri F et al (2021) Long-term outcomes (15 years) after Subthalamic Nucleus Deep Brain Stimulation in patients with Parkinson Disease. Neurology. https://doi.org/10.1212/WNL.0000000000012246CrossRefPubMedPubMedCentral

Brinker D, Smilowska K, Paschen S et al (2023) How to use the New European Academy of Neurology/Movement Disorder Society European Section Guideline for Invasive Therapies in Parkinson’s Disease. Mov Disord Clin Pract. https://doi.org/10.1002/mdc3.13962CrossRefPubMedPubMedCentral

Busk K, Nyholm D (2012) Long-term 24-h levodopa/carbidopa gel infusion in Parkinson’s disease. Parkinsonism Relat Disord 18:1000–1001. https://doi.org/10.1016/j.parkreldis.2012.04.010CrossRefPubMed

Cif L, Hariz M (2017) Seventy years with the Globus Pallidus: pallidal surgery for Movement disorders between 1947 and 2017. Mov Disord 32:972–982. https://doi.org/10.1002/mds.27054CrossRefPubMed

Cruse B, Morales-Briceño H, Chang FCF et al (2018) 24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease. NPJ Parkinsons Dis 4:34. https://doi.org/10.1038/s41531-018-0070-4CrossRefPubMedPubMedCentral

Dafsari HS, Petry-Schmelzer JN, Ray-Chaudhuri K et al (2018) Non-motor outcomes of subthalamic stimulation in Parkinson’s disease depend on location of active contacts. Brain Stimul 11:904–912. https://doi.org/10.1016/j.brs.2018.03.009CrossRefPubMed

Davis KL, Edin HM, Allen JK (2010) Prevalence and cost of medication nonadherence in Parkinson’s disease: evidence from administrative claims data. Mov Disord 25:474–480. https://doi.org/10.1002/mds.22999CrossRefPubMed

Debove I, Paschen S, Amstutz D et al (2024) Management of Impulse Control and Related disorders in Parkinson’s Disease: An Expert Consensus. https://doi.org/10.1002/mds.29700. Mov Disord

Deuschl G, Schade-Brittinger C, Krack P et al (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355:896–908. https://doi.org/10.1056/NEJMoa060281CrossRefPubMed

Deuschl G, Antonini A, Costa J et al (2022) European Academy of Neurology/Movement Disorder Society-European Section Guideline on the treatment of Parkinson’s Disease: I. Invasive therapies. Mov Disord 37:1360–1374. https://doi.org/10.1002/mds.29066CrossRefPubMed

Fasano A, Fung VSC, Lopiano L et al (2019) Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurol 19:50. https://doi.org/10.1186/s12883-019-1276-8CrossRefPubMedPubMedCentral

Fasano A, Gurevich T, Jech R et al (2021) Concomitant medication usage with levodopa-carbidopa intestinal gel: results from the COSMOS Study. Mov Disord 36:1853–1862. https://doi.org/10.1002/mds.28596CrossRefPubMedPubMedCentral

Fernandez HH, Standaert DG, Hauser RA et al (2015) Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease: final 12-month, open-label results. Mov Disord 30:500–509. https://doi.org/10.1002/mds.26123CrossRefPubMed

Follett KA, Weaver FM, Stern M et al (2010) Pallidal versus subthalamic deep-brain stimulation for Parkinson’s disease. N Engl J Med 362:2077–2091. https://doi.org/10.1056/NEJMoa0907083CrossRefPubMed

Freire-Alvarez E, Kurča E, Lopez Manzanares L et al (2021) Levodopa-carbidopa intestinal gel reduces Dyskinesia in Parkinson’s Disease in a Randomized Trial. Mov Disord 36:2615–2623. https://doi.org/10.1002/mds.28703CrossRefPubMedPubMedCentral

Georgiev D, Delalić S, Zupančič Križnar N et al (2022) Switching and combining device-aided therapies in Advanced Parkinson’s Disease: a double Centre Retrospective Study. Brain Sci 12:343. https://doi.org/10.3390/brainsci12030343CrossRefPubMedPubMedCentral

Geraedts VJ, Feleus S, Marinus J et al (2020) What predicts quality of life after subthalamic deep brain stimulation in Parkinson’s disease? A systematic review. Eur J Neurol 27:419–428. https://doi.org/10.1111/ene.14147CrossRefPubMed

Groppa S, Gonzalez-Escamilla G, Tinkhauser G et al (2023) Perspectives of implementation of closed-Loop Deep Brain Stimulation: from neurological to Psychiatric disorders. Stereotact Funct Neurosurg 1–15. https://doi.org/10.1159/000535114

Grund KE, Zipfel A, Duckworth-Mothes B, Jost WH (2023) Optimised endoscopic access for intrajejunal levodopa application in idiopathic Parkinson’s syndrome. J Neural Transm (Vienna). https://doi.org/10.1007/s00702-023-02601-0CrossRefPubMed

Hacker ML, Meystedt JC, Turchan M et al (2023) Eleven-Year outcomes of Deep Brain Stimulation in Early-Stage Parkinson Disease. Neuromodulation 26:451–458. https://doi.org/10.1016/j.neurom.2022.10.051CrossRefPubMed

Hardoff R, Sula M, Tamir A et al (2001) Gastric emptying time and gastric motility in patients with Parkinson’s disease. Mov Disord 16:1041–1047. https://doi.org/10.1002/mds.1203CrossRefPubMed

Hechtner MC, Vogt T, Zöllner Y et al (2014) Quality of life in Parkinson’s disease patients with motor fluctuations and dyskinesias in five European countries. Parkinsonism Relat Disord 20:969–974. https://doi.org/10.1016/j.parkreldis.2014.06.001CrossRefPubMed

Honey CR, Hamani C, Kalia SK et al (2017) Deep brain stimulation target selection for Parkinson’s Disease. Can J Neurol Sci 44:3–8. https://doi.org/10.1017/cjn.2016.22CrossRefPubMed

Jost ST, Sauerbier A, Visser-Vandewalle V et al (2020) A prospective, controlled study of non-motor effects of subthalamic stimulation in Parkinson’s disease: results at the 36-month follow-up. J Neurol Neurosurg Psychiatry 91:687–694. https://doi.org/10.1136/jnnp-2019-322614CrossRefPubMed

Jost ST, Visser-Vandewalle V, Rizos A et al (2021) Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. NPJ Parkinsons Dis 7:48. https://doi.org/10.1038/s41531-021-00174-xCrossRefPubMedPubMedCentral

Katzenschlager R, Poewe W, Rascol O et al (2018) Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol 17:749–759. https://doi.org/10.1016/S1474-4422(18)30239-4CrossRefPubMed

Kleiner-Fisman G, Herzog J, Fisman DN et al (2006) Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 21 Suppl 14S290–304. https://doi.org/10.1002/mds.20962

Krack P, Pollak P, Limousin P et al (1998) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson’s disease. Brain 121(Pt 3):451–457. https://doi.org/10.1093/brain/121.3.451CrossRefPubMed

Kukkle PL, Garg D, Merello M (2023) Continuous subcutaneous infusion delivery of apomorphine in Parkinson’s Disease: a systematic review. Mov Disord Clin Pract 10:1253–1267. https://doi.org/10.1002/mdc3.13810CrossRefPubMed

Kurtis MM, Rajah T, Delgado LF, Dafsari HS (2017) The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence. NPJ Parkinsons Dis 3:16024. https://doi.org/10.1038/npjparkd.2016.24CrossRefPubMedPubMedCentral

Lange F, Steigerwald F, Malzacher T et al (2021) Reduced Programming Time and strong Symptom Control even in Chronic Course through Imaging-based DBS Programming. Front Neurol 12:785529. https://doi.org/10.3389/fneur.2021.785529CrossRefPubMedPubMedCentral

Limousin P, Krack P, Pollak P et al (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 339:1105–1111. https://doi.org/10.1056/NEJM199810153391603CrossRefPubMed

Luquin M-R, Kulisevsky J, Martinez-Martin P et al (2017) Consensus on the definition of Advanced Parkinson’s Disease: a neurologists-based Delphi Study (CEPA Study). Parkinsons Dis 2017:4047392. https://doi.org/10.1155/2017/4047392CrossRefPubMedPubMedCentral

Mahlknecht P, Foltynie T, Limousin P, Poewe W (2022) How does Deep Brain Stimulation change the course of Parkinson’s Disease? Mov Disord 37:1581–1592. https://doi.org/10.1002/mds.29052CrossRefPubMedPubMedCentral

Marras C, Lang A, Krahn M et al (2004) Quality of life in early Parkinson’s disease: impact of dyskinesias and motor fluctuations. Mov Disord 19:22–28. https://doi.org/10.1002/mds.10642CrossRefPubMed

Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM et al (2011) The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord 26:399–406. https://doi.org/10.1002/mds.23462CrossRefPubMed

Martinez-Martin P, Reddy P, Katzenschlager R et al (2015) EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson’s disease. Mov Disord 30:510–516. https://doi.org/10.1002/mds.26067CrossRefPubMed

Mathur S, Stamford J (2021) Bringing Advanced therapies for Parkinson’s Disease to the clinic: the patient’s perspective. J Parkinson’s Disease 11:S141. https://doi.org/10.3233/JPD-212650CrossRef

Meira B, Degos B, Corsetti E et al (2021) Long-term effect of apomorphine infusion in advanced Parkinson’s disease: a real-life study. npj Parkinsons Dis 7:1–11. https://doi.org/10.1038/s41531-021-00194-7CrossRef

Nijhuis FAP, Esselink R, de Bie RMA et al (2021) Translating evidence to Advanced Parkinson’s Disease patients: a systematic review and Meta-analysis. Mov Disord 36:1293–1307. https://doi.org/10.1002/mds.28599CrossRefPubMedPubMedCentral

Nyholm D, Nilsson Remahl AIM, Dizdar N et al (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 64:216–223. https://doi.org/10.1212/01.WNL.0000149637.70961.4CCrossRefPubMed

Odekerken VJJ, van Laar T, Staal MJ et al (2013) Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study): a randomised controlled trial. Lancet Neurol 12:37–44. https://doi.org/10.1016/S1474-4422(12)70264-8CrossRefPubMed

Odekerken VJJ, Boel JA, Schmand BA et al (2016) GPi vs STN deep brain stimulation for Parkinson disease: three-year follow-up. Neurology 86:755–761. https://doi.org/10.1212/WNL.0000000000002401CrossRefPubMed

Olanow CW, Obeso JA, Stocchi F (2006) Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol 5:677–687. https://doi.org/10.1016/S1474-4422(06)70521-XCrossRefPubMed

Olanow CW, Kieburtz K, Odin P et al (2014) Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 13:141–149. https://doi.org/10.1016/S1474-4422(13)70293-XCrossRefPubMed

Olanow CW, Factor SA, Espay AJ et al (2020) Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol 19:135–144. https://doi.org/10.1016/S1474-4422(19)30396-5CrossRefPubMed

Öthman M, Widman E, Nygren I, Nyholm D (2021) Initial experience of the levodopa-entacapone-carbidopa intestinal gel in clinical practice. J Pers Med 11:254. https://doi.org/10.3390/jpm11040254CrossRefPubMedPubMedCentral

Pal G, Mangone G, Hill EJ et al (2022) Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive effects in GBA Mutation Carriers. Ann Neurol 91:424–435. https://doi.org/10.1002/ana.26302CrossRefPubMedPubMedCentral

Pflug C, Bihler M, Emich K et al (2018) Critical Dysphagia is common in Parkinson Disease and occurs even in early stages: a prospective cohort study. Dysphagia 33:41–50. https://doi.org/10.1007/s00455-017-9831-1CrossRefPubMed

Pürner D, Hormozi M, Weiß D et al (2023) Nationwide Retrospective Analysis of Combinations of Advanced Therapies in patients with Parkinson Disease. Neurology 101:e2078–e2093. https://doi.org/10.1212/WNL.0000000000207858CrossRefPubMed

Qian K, Wang J, Rao J et al (2023) Intraoperative microelectrode recording under general anesthesia guided subthalamic nucleus deep brain stimulation for Parkinson’s disease: one institution’s experience. Front Neurol 14:1117681. https://doi.org/10.3389/fneur.2023.1117681CrossRefPubMedPubMedCentral

Rajan R, Garg K, Srivastava AK, Singh M (2022) Device-assisted and Neuromodulatory therapies for Parkinson’s Disease: A Network Meta-Analysis. Mov Disord 37:1785–1797. https://doi.org/10.1002/mds.29160CrossRefPubMed

Regidor I, Benita V, Del Álamo de Pedro M et al (2017) Duodenal levodopa infusion for long-term deep brain stimulation-refractory symptoms in Advanced Parkinson Disease. Clin Neuropharmacol 40:103–107. https://doi.org/10.1097/WNF.0000000000000216CrossRefPubMed

Reker P, Dembek TA, Becker J et al (2016) Directional deep brain stimulation: a case of avoiding dysarthria with bipolar directional current steering. Parkinsonism Relat Disord 31:156–158. https://doi.org/10.1016/j.parkreldis.2016.08.007CrossRefPubMed

Rolland A-S, Touzet G, Carriere N et al (2024) The use of image guided programming to Improve Deep Brain Stimulation workflows with directional leads in Parkinson’s Disease. J Parkinsons Dis 14:111–119. https://doi.org/10.3233/JPD-225126CrossRefPubMedPubMedCentral

Rosebraugh M, Liu W, Neenan M, Facheris MF (2021a) Foslevodopa/Foscarbidopa is well tolerated and maintains stable levodopa and carbidopa exposure following subcutaneous infusion. J Parkinsons Dis 11:1695–1702. https://doi.org/10.3233/JPD-212813CrossRefPubMedPubMedCentral

Rosebraugh M, Voight EA, Moussa EM et al (2021b) Foslevodopa/Foscarbidopa: a New Subcutaneous Treatment for Parkinson’s Disease. Ann Neurol 90:52–61. https://doi.org/10.1002/ana.26073CrossRefPubMedPubMedCentral

Schnitzler A, Mir P, Brodsky MA et al (2022) Directional deep brain stimulation for Parkinson’s Disease: results of an international crossover study with randomized, double-blind primary endpoint. Neuromodulation 25:817–828. https://doi.org/10.1111/ner.13407CrossRefPubMed

Schröter N, Jost WH, Rijntjes M et al (2024) Synergien statt Rivalitäten – die missverstandenen Rollen Von Kontinuierlicher Intrajejunaler Levodopatherapie Und Tiefer Hirnstimulation in Der Behandlung Des Morbus Parkinson – Eine Expertenmeinung. https://doi.org/10.1055/a-2238-1641. Fortschr Neurol Psychiatr

Schuepbach WMM, Rau J, Knudsen K et al (2013) Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 368:610–622. https://doi.org/10.1056/NEJMoa1205158CrossRefPubMed

Senek M, Nielsen EI, Nyholm D (2017) Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: a randomized crossover study. Mov Disord 32:283–286. https://doi.org/10.1002/mds.26855CrossRefPubMed

Sesar Á, Fernández-Pajarín G, Ares B et al (2019) Continuous subcutaneous apomorphine in advanced Parkinson’s disease patients treated with deep brain stimulation. J Neurol 266:659–666. https://doi.org/10.1007/s00415-019-09184-5CrossRefPubMed

Soileau MJ, Aldred J, Budur K et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson’s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21:1099–1109. https://doi.org/10.1016/S1474-4422(22)00400-8CrossRefPubMed

Storch A, Schneider CB, Wolz M et al (2013) Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 80:800–809. https://doi.org/10.1212/WNL.0b013e318285c0edCrossRefPubMed

Südmeyer P, Siebecker, et al (2023) Real-world utility of MANAGE PD tool by physicians and patients in Germany. Mov Disorders MovDis. https://doi.org/10.1002/mds.29544CrossRef

Timpka J, Nitu B, Datieva V et al (2017) Device-aided treatment strategies in Advanced Parkinson’s Disease. Int Rev Neurobiol 132:453–474. https://doi.org/10.1016/bs.irn.2017.03.001CrossRefPubMed

Todorova A, Chaudhuri KR (2013) Subcutaneous apomorphine and non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 19:1073–1078. https://doi.org/10.1016/j.parkreldis.2013.08.012CrossRefPubMed

Todorova A, Samuel M, Brown RG, Chaudhuri KR (2015) Infusion therapies and development of Impulse Control disorders in Advanced Parkinson Disease: clinical experience after 3 years’ follow-up. Clin Neuropharmacol 38:132. https://doi.org/10.1097/WNF.0000000000000091CrossRefPubMed

Trenkwalder C, Chaudhuri KR, Ruiz PJG et al (2015) Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson’s disease – clinical practice recommendations. Parkinsonism Relat Disord 21:1023–1030. https://doi.org/10.1016/j.parkreldis.2015.06.012CrossRefPubMed

van Laar T, Postma AG, Drent M (2010) Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson’s disease and pre-existing visual hallucinations. Parkinsonism Relat Disord 16:71–72. https://doi.org/10.1016/j.parkreldis.2009.05.006CrossRefPubMed

Weaver FM, Follett KA, Stern M et al (2012) Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology 79:55–65. https://doi.org/10.1212/WNL.0b013e31825dcdc1CrossRefPubMedPubMedCentral

Title: Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Authors: Nils Schröter
Bastian E. A. Sajonz
Wolfgang H. Jost
Michel Rijntjes
Volker A. Coenen
Sergiu Groppa
Publication date: 13-04-2024
Publisher: Springer Vienna
Keywords: Deep Brain Stimulation
Parkinson's Disease
Levodopa
Apomorphine
Carbidopa
Entacapone
Published in: Journal of Neural Transmission
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-024-02773-3

2024 ASCO Annual Meeting

Springer Medicine

Advanced therapies in Parkinson’s disease: an individualized approach to their indication

Abstract

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content